VILDAX Tablets provide an established, clinically unified anti-hyperglycemic monotherapy carefully developed for the continuous management and physiological stabilization of Type 2 Diabetes Mellitus. When standard metabolic pathways face progressive insulin resistance and pancreatic beta-cell fatigue, protecting and enhancing natural hormone loops becomes essential. This advanced formulation delivers a modern DPP-4 inhibitor within a standardized 50 mg unit, helping to maintain stable fasting and post-meal blood glucose targets safely over a long-term care routine.
The active component, Vildagliptin (50 mg), functions dynamically via highly targeted metabolic tracks:
-
Selective DPP-4 Inhibition: It operates as a potent and selective inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme. By blocking this enzyme, it prevents the rapid degradation of endogenous incretin hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
-
Glucose-Dependent Pancreatic Regulation: Prolonged incretin activity enhances pancreatic sensitivity to glucose. This prompts beta-cells to secrete insulin in a glucose-dependent manner (exclusively when blood sugar levels are elevated) while simultaneously suppressing alpha-cell glucagon secretion. This dual action dramatically drops inappropriate hepatic gluconeogenesis (sugar release from the liver) and controls post-meal spikes around the clock.
Key Benefits
-
Smart Sugar Management: Triggers insulin secretion exclusively in response to elevated blood glucose levels, significantly lowering the statistical risk of sudden drops (hypoglycemia).
-
Fasting & Post-Meal Balance: Effectively smooths out post-meal blood sugar surges while keeping overnight liver glucose production tightly controlled.
-
Pancreatic Preservation Core: Supports natural pancreatic islet cell responsiveness, helping to stabilize long-term HbA1c trends.
-
Weight-Neutral Metabolic Care: Provides intensive glycemic control without causing progressive weight gain or fluid retention issues.
-
Trusted Quality Control: Manufactured under strict pharmaceutical protocols of DH, ensuring exceptional dissolution uniformity and steady structural bioavailability.
Directions for Use
-
Take exactly as directed by your diabetologist, endocrinologist, or primary healthcare physician.
-
VILDAX is typically administered either once daily (50 mg in the morning) or twice daily (50 mg in the morning and 50 mg at night) based on your therapeutic tracking layout.
-
Can be taken comfortably either with or after meals.
-
Swallow the tablet whole with a full glass of plain water. Do not crush, split, or chew it.
-
Maintain complete daily consistency alongside a low-glycemic, balanced diet; missing doses can cause blood sugar levels to destabilize behind tracking boundaries.
Safety & Precautions
-
Do not modify your dose or halt usage suddenly without professional medical instruction, as blood sugar levels can rise rapidly.
-
Contraindicated in Type 1 Diabetes: This medication is indicated exclusively for Type 2 Diabetes profiles; it must not be used for managing type 1 diabetes or diabetic ketoacidosis.
-
Monitor your blood glucose baselines, HbA1c metrics, and liver function parameters (LFTs) regularly throughout long-term care routines, as DPP-4 inhibitors require routine professional medical monitoring.
-
Inform your specialist before initialization if you have an underlying history of severe liver vulnerabilities, advanced renal impairment, heart failure conditions, or acute pancreatitis patterns.
-
Keep out of reach of children.
Storage
-
Store in a cool, dry place below 30°C.
-
Protect from direct sunlight, excessive heat sources, and environmental room moisture pools.
-
Always keep the tablets safely sealed inside their original protective blister packaging layout until the exact moment of intake to shield the core components from ambient room humidity.
